Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Projects Annual Medicare Rx Market Of $181 Bil. In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency projects that total payments to Medicare Rx plans over fiscal years 2006-2015 will be $1.2 tril. CMS stresses that the new cost projections are consistent with previous estimates, plus two additional years of the drug benefit in action.

You may also be interested in...



Medicare Part D Benefit Pegged At $53.6 Bil. For 2006 By House Panel

The amount matches the estimate in the Administration’s budget request for the first nine months of the Rx drug benefit. A vote on the House Appropriations subcommittee’s mark by the full committee is slated for June 15, but may be rescheduled for June 16.

Medicare Part D Benefit Pegged At $53.6 Bil. For 2006 By House Panel

The amount matches the estimate in the Administration’s budget request for the first nine months of the Rx drug benefit. A vote on the House Appropriations subcommittee’s mark by the full committee is slated for June 15, but may be rescheduled for June 16.

HHS Touts MMA Drug Provisions As Counterweight To High Medicare Costs

E-prescribing, medication therapy management, the availability of generics through Part D, and a focus on drug effectiveness data will bolster Medicare’s fiscal integrity, HHS says. The 2005 Medicare Trustees Report projects that the hospital insurance trust fund will be insolvent in 2020.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel